<DOC>
	<DOC>NCT01690559</DOC>
	<brief_summary>This study is a post-marketing surveillance in Japan to investigate the safety especially focusing on injection site adverse events and efficacy in patients with Ciprofloxacin iv administration without dilution in the daily practice.It is a local prospective and observational study of patients who have received Ciproxan intravenously for sepsis, secondary skin infections followed by superficial burn, post-surgical or post-traumatic, pneumonia, peritonitis, cholecystitis, cholangitis, anthrax. A total of 500 patients are to be enrolled and assessed during the period of treatment with Ciproxan.</brief_summary>
	<brief_title>Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution</brief_title>
	<detailed_description />
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>The mentioned bellow patients caused by the following bacteria which are sensitive to this drug: Indicated microorganisms:Staphylococcus, Enterococcus, Bacillus anthracis, Escherichia coli, Klebsiella , Enterobacter, Pseudomonas aeruginosa, Legionella. Indications: Sepsis, Secondary skin infections (superficial burn, operative wounds, trauma), Pneumonia, Peritonitis, Cholecystitis, Cholangitis, Anthrax The patients treated with this drug without dilution due to strict restriction of fluid intake. In hospitalized patients who retain consciousness ,and at the same time who are able to report (such as vascular pain) side effects.. Patients who are contraindicated based on the product label.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>sepsis</keyword>
	<keyword>infection</keyword>
	<keyword>pneumonia</keyword>
	<keyword>peritonitis</keyword>
	<keyword>cholecystitis</keyword>
	<keyword>cholangitis</keyword>
	<keyword>anthrax</keyword>
</DOC>